MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$150.34
−1.31%Jun 22, 2026, 21:00 UTC
Fred Alger Management, LLC announced the quarterly rebalancing of the Alger Russell Innovation Index, effective after the close of trading on June 26, 2026, with additions and deletions of several companies.
Source:Jun 12, 2026, 20:10 UTC
The U.S. FDA approved KEYTRUDA and KEYTRUDA QLEX, each in combination with WELIREG, for adjuvant treatment of certain patients with clear cell renal cell carcinoma.
Source:Jun 11, 2026, 10:45 UTC
Merck Animal Health, a division of Merck & Co., has signed a definitive agreement to acquire TARGAN, a privately held biodevice company for the poultry industry, for an undisclosed price.
Jun 9, 2026, 20:36 UTC
Gilead and Merck end a lung cancer study.
Source:Jun 8, 2026, 20:30 UTC
Merck and Gilead discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 study based on an external Data Monitoring Committee recommendation.
Source:Jun 8, 2026, 12:00 UTC
Rejuvenate Bio announced a strategic R&D collaboration with Merck Animal Health and a $6 million financing.
Source:Jun 1, 2026, 21:35 UTC
The Coalition for Epidemic Preparedness Innovations (CEPI) announced approximately $62 million in funding to three entities to fast-track development and testing of vaccines targeting the Bundibugyo ebolavirus.
Source:Jun 1, 2026, 18:00 UTC
Merck's calderasib plus Keytruda received FDA Breakthrough Therapy designation for newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.
Source:
← PreviousPage 3